Form 4 for VRTX Vertex Pharmaceuticals
Accepted 2023-01-25 00:00:00 ET · period of report 2023-01-23 · accession 0001209191-23-004816 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2023-01-25 | 2023-01-23+ | VRTX | Lee Yuchun | Dir | M - OptEx | $72.14 | +6,129 | 4,004 | New | +$442.1K |
| DM | 2023-01-25 | 2023-01-23+ | VRTX | Lee Yuchun | Dir | S - Sale+OE | $312.46 | -6,129 | 3,364 | -65% | -$1.92M |
| DM | 2023-01-25 | 2023-01-23+ | VRTX | Lee Yuchun | Dir | M - OptEx | $0.00 | -6,129 | 13.4K | -31% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-01-24 | M | A | 4,000 | $72.14 | 5,875 | D | — | — | |
| 2 | Common | Common Stock | 2023-01-23 | M | A | 2,129 | $72.14 | 4,004 | D | — | — | |
| 3 | Common | Common Stock | 2023-01-23 | S | D | 2,129 | $312.02 | 1,875 | D | — | — | (F2) Mr. Lee undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. (F3) Open market sales reported on this line occurred at a weighted average price of $312.02 (range $312.00 to $312.17). |
| 4 | Common | Common Stock | 2023-01-24 | S | D | 1,489 | $313.36 | 1,875 | D | — | — | (F2) Mr. Lee undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. (F5) Open market sales reported on this line occurred at a weighted average price of $313.36 (range $313.00 to $313.73). |
| 5 | Common | Common Stock | 2023-01-24 | S | D | 2,511 | $312.29 | 3,364 | D | — | — | (F2) Mr. Lee undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. (F4) Open market sales reported on this line occurred at a weighted average price of $312.29 (range $312.00 to $312.92). |
| 6 | Derivative | Stock Option (Right to Buy) | 2023-01-24 | M | D | 4,000 | $0.00 | 9,429 | D | $72.14 · — to 2024-05-31 | 4,000 Common Stock | (F6) Fully vested. |
| 7 | Derivative | Stock Option (Right to Buy) | 2023-01-23 | M | D | 2,129 | $0.00 | 13,429 | D | $72.14 · — to 2024-05-31 | 2,129 Common Stock | (F6) Fully vested. |